A
Anne Marie C. Dingemans
Researcher at Erasmus University Medical Center
Publications - 8
Citations - 631
Anne Marie C. Dingemans is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Cancer & Health care. The author has an hindex of 4, co-authored 8 publications receiving 392 citations. Previous affiliations of Anne Marie C. Dingemans include Maastricht University Medical Centre.
Papers
More filters
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
Anne Marie C. Dingemans,Ross A. Soo,Abdul Rahman Jazieh,Shawn J. Rice,Young Tae Kim,Lynette L.S. Teo,Graham W. Warren,Shu-Yuan Xiao,Shu-Yuan Xiao,Egbert F. Smit,Joachim G.J.V. Aerts,Soon Ho Yoon,Giulia Veronesi,Francesco De Cobelli,Suresh S. Ramalingam,Marina Chiara Garassino,Murry W. Wynes,Madhusmita Behera,John B. A. G. Haanen,Shun Lu,Solange Peters,Myung-Ju Ahn,Giorgio V. Scagliotti,Alex A. Adjei,Chandra P. Belani +24 more
TL;DR: A practical multidisciplinary and international overview to assist in treatment for lung cancer patients during this pandemic, with the caveat that evidence is lacking in many areas.
Journal ArticleDOI
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
Jennifer G. Whisenant,Annalisa Trama,Valter Torri,Alessandro De Toma,Giuseppe Viscardi,Alessio Cortellini,Olivier Michielin,Fabrice Barlesi,Fabrice Barlesi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Vera Pancaldi,Ross A. Soo,Natasha B. Leighl,Solange Peters,Heather A. Wakelee,Marina Chiara Garassino,Leora Horn +17 more
TL;DR: Patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities, and physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19.
Journal ArticleDOI
Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice.
Jules L. Derks,Nicole Rijnsburger,B.C.M. Hermans,Laura Moonen,Lisa M. Hillen,Jan H. von der Thüsen,Michael A. den Bakker,Robert J. van Suylen,Ernst-Jan M. Speel,Anne Marie C. Dingemans,Anne Marie C. Dingemans +10 more
TL;DR: In this article, a review of clinical and pathologic issues and informative molecular markers are discussed, including the preferred outcome parameter for curatively resected low-grade pulmonary neuroendocrine neoplasm (carcinoid), for example, overall survival or recurrence-free interval.
Journal ArticleDOI
LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
Sjoukje F. Oosting,A.A.M. Van der Veldt,Corine H. GeurtsvanKessel,Rudolf S N Fehrmann,R van Binnendijk,Anne Marie C. Dingemans,Egbert F. Smit,Thijo J N Hiltermann,G. den Hartog,Mathilde Jalving,T. Westphal,A. Battacharya,M. van der Heiden,Christian U. Blank,Marion Koopmans,C. A. van Els,Nynke Y. Rots,D. van Baarle,J.B.A.G. Haanen,E.G.E. de Vries +19 more
TL;DR: In this paper, a prospective multicenter non-inferiority trial comprises four cohorts: individuals without cancer (A) and patients with solid tumors who were treated with immunotherapy (B), chemotherapy (C) or chemo-immunotherapy (D). Participants received two mRNA-1273 vaccinations 28 days apart.